1098 related articles for article (PubMed ID: 10854085)
1. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
2. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Oparil S
Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
[TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonists in arterial hypertension.
Hernández-Hernández R; Velasco M; Armas-Hernández MJ; Armas-Padilla MC
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S69-72. PubMed ID: 10854084
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists role in arterial hypertension.
Hernández-Hernández R; Sosa-Canache B; Velasco M; Armas-Hernández MJ; Armas-Padilla MC; Cammarata R
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S93-9. PubMed ID: 11986904
[TBL] [Abstract][Full Text] [Related]
6. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
8. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Unger T
Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of angiotensin II receptor antagonists.
Timmermans PB
Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
[TBL] [Abstract][Full Text] [Related]
11. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
12. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
Ball SG; White WB
Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
[TBL] [Abstract][Full Text] [Related]
13. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Elmfeldt D; Olofsson B; Meredith P
Blood Press; 2002; 11(5):293-301. PubMed ID: 12458652
[TBL] [Abstract][Full Text] [Related]
14. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
16. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
17. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
Thomas GN; Chan P; Tomlinson B
Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
[TBL] [Abstract][Full Text] [Related]
18. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockers: review of the binding characteristics.
Siragy H
Am J Cardiol; 1999 Nov; 84(10A):3S-8S. PubMed ID: 10588088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
